ทางการเงิน สำหรับงวดหกเดือนสิ้นสุดวันที่ 30 มิถุนายน 2563 และ 30 มิถุนายน 2562 ดังนี้: Q2 2563 Q2 2562 YoY change YoY % change หน่วย: ล้านบาท รายได้จากการขายและบริการ 232.44 229.27 3.17 1% รายได้อ่ืน 3.27

-20 % Change Amount % Amount % Amount % Q3-20 VS Q3-19 Q3-20 VS Q2-20 Sales revenue 17,540 100.0 12,404 100.0 14,491 100.0 41.4 21.0 Gross profit 4,574 26.1 2,373 19.1 3,892 26.9 92.8 17.5 Operating

% Change Amount % Amount % Amount % Q1-21 VS Q1-20 Q1-21 VS Q4-20 Sales revenue 19,039 100.0 12,755 100.0 18,498 100.0 49.3 2.9 Gross profit 4,103 21.6 2,586 20.3 4,067 22.0 58.7 0.9 Operating profit 1,372

ratio did not exceed 3.00 times, which is the covenant for bank loans and debentures. 3 Income Statement For the year ended December 31 Change Unit: Million Baht 2019 2018 Amount % Revenues from

% Change Amount % Amount % Amount % Q1-20 VS Q1-19 Q1-20 VS Q4-19 Sales revenue 12,680 100.0 12,949 100.0 11,707 100 (2.1) 8.3 Gross profit 2,586 20.4 2,978 23.0 2,155 18.4 (13.2) 20.0 Operating profit 549

Limited, equivalent to 3,311,172.50 baht. After the transaction is completed, CWTG will hold approximately 100% of the shares in GP1 And all sold. Shareholding structure: Before Change Shareholding

results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech

three-month period ended Q1-2020 Q1-2019 Change 2020 2019 THB Mn % Sales of electricity - FiT 623.1 580.4 42.7 7.4 FiT Premium 43.7 42.6 1.1 2.6 Sales of electricity to Industrial Users (IU) 4.7 2.4 2.3

% 2.2% 29.9% 27.2% (2.7%) Net profit margin1 (%) 17.7% 8.1% (9.6%) 19.7% 7.1% (12.6%) Number of branches as at Dec 312 38 39 3% 38 39 3% 2019 2020 Change +/(-) Change +/(-) Q4/19 Q4/20 Operating highlight

Discussion & Analysis Q2/2021 Operating Highlights in Q2/2021 Q2/20 Q2/21 Change +/(-) 1H/20 1H/21 Change +/(-) (THB million) %YoY %YoY Operating Revenue 144 137 (5%) 363 317 (13%) Gross Profit 79 77 (3%) 216